New HNF-1&#945; nonsense mutation causes maturity-onset diabetes of the young type 3 by Nogaroto, Viviane et al.
RAPID COMMUNICATION
New HNF-1a nonsense mutation causes
maturity-onset diabetes of the young type 3
Viviane Nogaroto,I Paulo Vinicius Svidnicki,I Naieli Bonatto,II Fa´bio Quirillo Mille´o,III
Mara Cristina de Almeida,I Marcelo Ricardo Vicari,I Roberto Ferreira ArtoniI
IDepartamento de Biologia Estrutural, Molecular e Gene´tica, Universidade Estadual de Ponta Grossa, Ponta Grossa, Parana´, Brazil. II Programa de Po´s-
Graduac¸a˜o em Gene´tica, Universidade Federal do Parana´, Curitiba, Parana´, Brazil. IIIDepartamento de Cirurgia, Hospital Vicentino da Sociedade
Beneficente Sa˜o Camilo, Ponta Grossa, Parana´, Brazil.
Email: vivianenogaroto@hotmail.com
Tel.: 55 42 3220-3739
Epidemiological studies indicate that approximately 5%
of people previously classified as type 2 diabetes mellitus
carriers and 10% of those considered as type 1 are, in fact,
carriers of maturity-onset diabetes of the young (MODY), a
subtype of non-insulin-dependent diabetes mellitus.1 This
monogenic form of diabetes is characterized by early onset
(usually under 25 years old), high penetrance and the
autosomal dominant mode of inheritance.2,3
Six MODY genes have already been identified. The
MODY 3 subtype, caused by mutations in the HNF-1a
(hepatocyte nuclear factor-1 alpha) gene,4 is the most
common Mendelian form of diabetes and it is found in
more than 60% of the cases classified as MODY, accounting
for 1–2% of all diabetic individuals.5 The diabetic phenotype
of the carriers of this mutation is due to altered gene
expression of pancreatic b-cells, mainly of the genes
encoding insulin, the glucose transporter Glut2, amino acid
transporters and some mitochondrial enzymes.6,7
The identification of the MODY genes has important
clinical implications for patients, and their correct diagnosis
is essential for a more appropriate treatment of the disease.
The aim of this study was to examine a family suspected of
carrying a type of MODY diabetes, searching for mutations
present in this syndrome and its correlation with the clinical
aspects of the patients.
This study received approval from the Ethics Committee
of the Universidade Estadual de Ponta Grossa (COEP
authorization no. 14/2009, protocol no. 00884/09) and
signed consent was obtained from all patients. Three
generations of a family from South Brazil with a history of
progressive and early diabetes, characteristics of MODY
3,2,3,5,8 were analyzed.
EDTA anticoagulant venous blood samples were col-
lected from the patients and the isolated genomic DNA9 was
used as template in a polymerase chain reaction. Because
MODY 3 is the most commonly occurring form of the
disease in Brazil,10 oligonucleotides were synthesized for
the flanking regions (introns) of the 10 exons of HNF-1a. The
samples were subjected to electrophoresis and purified, and
then submitted for automatic nucleotide sequencing.
After nucleotide alignment, the presence of a mutation in
exon 2 of the HNF1-a gene was detected in some members
of the family: the proband and her daughters (Figure 1). The
transition of a guanine to an adenine nucleotide at position
339 of codon 113 (TGGRTGA) has generated a nonsense
mutation in this position (W113X), not yet described in the
literature, which inhibits the formation of a functional
protein in the affected individuals. More than 120 mutations
have already been identified in the HNF1-a gene, e.g.
missense, nonsense, frameshift and splice-site MODY
mutations, in all exons analyzed.11 The majority of muta-
tions in the HNF-1a protein lead to the formation of
nonfunctional heterodimers with the product of the normal
HNF-1a allele, preventing them from binding to DNA.
All the affected members analyzed in this study showed
hyperglycemia at young ages, and the proband, now 38 years
old, already manifests impaired vision and microcirculation,
characteristics of a progressive syndrome, such as MODY 3.
Some reports may explain the precocious manifestation of the
disease in individuals of this study. According to Harries
et al.12 the age of MODY 3 diagnosis is determined, in part, by
the location of the mutation; mutations in the proximal
segment of theHNF-1a gene should give rise to a more severe
phenotype than mutations in the distal regions. Furthermore,
the age at diagnosis of diabetes varies according to the type
of the HNF-1a mutations: the median age at diagnosis was
lower in patients with truncating mutations than in those
with missense mutations.13
Functionally, the HNF-1a protein can be divided in three
regions: amino-terminal dimerization domain (amino acids
1–32), homeodomain binding domain (203–276) and trans-
activation carboxyl-terminal domain (281–631).14 The muta-
tions in this protein are more frequent in the homeodomain
regions and in a near amino-terminal region, between
residues 91 and 185,15,16 in agreement with our findings
(mutation at amino acid 113). This region is responsible for
binding and specificity in the interaction with DNA.15,17
Studies indicated that suppression of HNF-1a function
affects b-cell metabolism leading to MODY 318 and
concluded that normal function of the HNF-1a protein is
required for correct transcription of the insulin gene.19
In conclusion, the data presented in this study describe a
new mutation for MODY type 3 and suggest functional sig-
nificance of this genetic alteration in the insulin secretion
process, besides highlighting the diagnostic importance of
this type of diabetes aiming the control and clinical follow up.
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Figure 1 – Heredogram representing three generations (I, II and III) of the family analyzed in this study. The arrow indicates the
proband and the asterisks (*) represent the members examined in this work.
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